» Articles » PMID: 35685993

Genomic Landscape of T-cell Lymphoblastic Lymphoma

Overview
Specialty Oncology
Date 2022 Jun 10
PMID 35685993
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: T-cell lymphoblastic lymphoma (T-LBL) is an aggressive neoplasm of precursor T cells, however, detailed genome-wide sequencing of large T-LBL cohorts has not been performed due to its rarity. The purpose of this study was to identify putative driver genes in T-LBL.

Methods: To gain insight into the genetic mechanisms of T-LBL development, we performed whole-exome sequencing on 41 paired tumor-normal DNA samples from patients with T-LBL.

Results: We identified 32 putative driver genes using whole-exome sequencing in 41 T-LBL cases, many of which have not previously been described in T-LBL, such as Janus kinase 3 (), Janus kinase 1 (), Runt-related transcription factor 1 () and Wilms' tumor suppressor gene 1 (). When comparing the genetic alterations of T-LBL to T-cell acute lymphoblastic leukemia (T-ALL), we found that JAK-STAT and RAS pathway mutations were predominantly observed in T-LBL (58.5% and 34.1%, respectively), whereas Notch and cell cycle signaling pathways mutations were more prevalent in T-ALL. Notably, besides notch receptor 1 (), mutational status of plant homeodomain (PHD)-like finger protein 6 () was identified as another independent factor for good prognosis. Of utmost interest is that co-existence of and mutation status might provide an alternative for early therapeutic stratification in T-LBL.

Conclusions: Together, our findings will not only provide new insights into the molecular and genetic mechanisms of T-LBL, but also have tangible implications for clinical practice.

Citing Articles

Retrospective analysis of clinical and molecular characteristics as prognostic factors in adult T-cell lymphoblastic lymphoma.

Ma L, Wang J, Zhao J, Zheng M, Wen X, Su L Am J Cancer Res. 2025; 14(12):5851-5862.

PMID: 39803658 PMC: 11711535. DOI: 10.62347/ZWAM1063.


Investigating the physiological role of S199A and S199D mutants of PHF6 protein in T-cell acute lymphoblastic leukemia.

Erdogan G, Ozes O, Kupesiz A, Yoldas S Turk J Med Sci. 2024; 53(5):1234-1243.

PMID: 38812997 PMC: 10763810. DOI: 10.55730/1300-0144.5689.


Synthesis, Characterization, and Antimicrobial and Antiproliferative Effects of CuO-TiO-Chitosan-Escin Nanocomposites on Human Leukemic MOLT4 Cells.

Elderdery A, Alhamidi A, Elkhalifa A, Althobiti M, Omer N, Alsugoor M Nanomaterials (Basel). 2022; 12(21).

PMID: 36364538 PMC: 9655830. DOI: 10.3390/nano12213753.

References
1.
Balbach S, Makarova O, Bonn B, Zimmermann M, Rohde M, Oschlies I . Proposal of a genetic classifier for risk group stratification in pediatric T-cell lymphoblastic lymphoma reveals differences from adult T-cell lymphoblastic leukemia. Leukemia. 2015; 30(4):970-3. DOI: 10.1038/leu.2015.203. View

2.
Callens C, Baleydier F, Lengline E, Ben Abdelali R, Petit A, Villarese P . Clinical impact of NOTCH1 and/or FBXW7 mutations, FLASH deletion, and TCR status in pediatric T-cell lymphoblastic lymphoma. J Clin Oncol. 2012; 30(16):1966-73. DOI: 10.1200/JCO.2011.39.7661. View

3.
Rohde M, Bonn B, Zimmermann M, Szczepanowski M, Damm-Welk C, Stanulla M . Multiplex ligation-dependent probe amplification validates LOH6q analyses and enhances insight into chromosome 6q aberrations in pediatric T-cell lymphoblastic leukemia and lymphoma. Leuk Lymphoma. 2014; 56(6):1884-7. DOI: 10.3109/10428194.2014.976820. View

4.
Yeh T, Liang D, Liu H, Jaing T, Chen S, Hou J . Clinical and biological relevance of genetic alterations in pediatric T-cell acute lymphoblastic leukemia in Taiwan. Pediatr Blood Cancer. 2018; 66(1):e27496. DOI: 10.1002/pbc.27496. View

5.
Waanders E, van der Velden V, van der Schoot C, van Leeuwen F, van Reijmersdal S, de Haas V . Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia. Leukemia. 2010; 25(2):254-8. DOI: 10.1038/leu.2010.275. View